Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription pharmaceuticals. The company primarily serves the hospital acute care, gastroenterology, and oncology markets in the United States. These medical specialties are characterized by relatively concentrated prescriber bases, which Cumberland believes can be effectively served by small, targeted sales forces.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Cumberland is actively engaged in research and development to enhance its product offerings and address unmet medical needs. The company's R&D efforts focus on advancing its existing product pipeline and exploring new therapeutic opportunities. Key initiatives include the development of ifetroban, a selective thromboxane-prostanoid receptor antagonist, which is in Phase II clinical trials for several indications. The U.S. FDA has granted ifetroban orphan drug designation and rare pediatric disease designation for Duchenne muscular dystrophy. Additionally, the company conducts various clinical trials to expand indications and improve formulations of existing products, such as Caldolor. Collaborative research agreements with institutions and support from federal grants are also part of the company's strategy to explore new pharmaceutical product candidates. The company operates through a dedicated clinical development team responsible for designing and executing clinical development strategies, including protocol design, statistical analysis plans, and the management of clinical trials. A majority-owned subsidiary that collaborates with academic research institutions to identify and support promising new product candidates. CET's role includes technology evaluation, product development, grant program management, and commercialization support. In FY2025, the company incurred expenses of US$5.6 million on R&D, which as a percentage of revenue, stood at 12.6%.